4D MOLECULAR THERAPEUTICS IN (FDMT)

Company Profile

4D Molecular Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. The company is headquartered in Emeryville, California and currently employs 171 full-time employees. The company went IPO on 2020-12-11. The firm has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Company Info

4D MOLECULAR THERAPEUTICS IN

5858 Horton Street #455, Emeryville

Emeryville CALIFORNIA

P: 15105052680

Employees: 171

Website: https://4dmoleculartherapeutics.com/